Drug intelligence / Profile preview

miR-X

Development stage: Preclinical
Lead developer: PURMX Therapeutics
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

miR-X is a preclinical-stage microRNA (miRNA) therapeutic being developed by PURMX Therapeutics for the treatment of solid tumors. As a small RNA nucleic acid drug, it is designed to modulate the activity of miR-X, a specific microRNA involved in oncogenic pathways. PURMX Therapeutics, a biopharmaceutical company spun off from Hiroshima University, utilizes a therapeutic strategy based on the concept of an 'aging switch' to fine-tune multiple target genes simultaneously using microRNA technology. miR-X is currently in the basic research phase of development, representing an earlier-stage program in PURMX's pipeline alongside other miRNA candidates.

Targets

Oncogenic messenger RNA transcripts containing microRNA seed-region binding sites

Beyond the preview

Go deeper on miR-X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-X.

Explore the full profile